Lexeo Therapeutics (LXEO) Assets Average (2023 - 2026)

Lexeo Therapeutics has disclosed Assets Average across 4 years of filings, most recently posting $259.5 million for Q1 2026.

• Assets Average for Q1 2026 came in at $259.5 million, up 90.38% year-over-year; the trailing twelve-month figure through Mar 2026 was $259.5 million (up 90.38% YoY), and the FY2025 annual result was $207.8 million, up 44.95% from the prior year.
• Assets Average came in at $259.5 million for Q1 2026 at Lexeo Therapeutics, up from $206.3 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $259.5 million in Q1 2026 to a low of $97.3 million in Q4 2023.
• The 4-year median for Assets Average is $168.5 million (2024), against an average of $173.3 million.
• Across the five-year window, Assets Average dropped 25.53% in 2025 and surged 90.38% in 2026, its largest moves.
• Lexeo Therapeutics' Assets Average stood at $97.3 million in 2023, then jumped by 64.91% to $160.4 million in 2024, then gained by 28.59% to $206.3 million in 2025, then climbed by 25.82% to $259.5 million in 2026.
• The last three Assets Average figures came in at $259.5 million (Q1 2026), $206.3 million (Q4 2025), and $160.0 million (Q3 2025), per Business Quant data.